LEVOSIMENDAN to Facilitate Weaning From ECMO in Severe Cardiogenic Shock Patients

Conditions:   Cardiogenic Shock;   Extracorporeal Membrane Oxygenation Complication Interventions:   Drug: Levosimendan;   Drug: Placebo of Levosimendan Sponsor:   Assistance Publique - Hôpitaux de Paris Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials